Optimal Vaccination Schedule Search Using Genetic Algorithm over MPI Technology

Overview

Journal BMC Med Inform Decis Mak

Publisher Biomed Central

Specialty Medical Informatics

Date 2012 Nov 15

PMID 23148787

Citations 1

Authors

Cristiano Calonaci

Ferdinando Chiacchio

Francesco Pappalardo

Affiliations

Soon will be listed here.

Abstract

Background: Immunological strategies that achieve the prevention of tumor growth are based on the presumption that the immune system, if triggered before tumor onset, could be able to defend from specific cancers. In supporting this assertion, in the last decade active immunization approaches prevented some virus-related cancers in humans. An immunopreventive cell vaccine for the non-virus-related human breast cancer has been recently developed. This vaccine, called Triplex, targets the HER-2-neu oncogene in HER-2/neu transgenic mice and has shown to almost completely prevent HER-2/neu-driven mammary carcinogenesis when administered with an intensive and life-long schedule.

Methods: To better understand the preventive efficacy of the Triplex vaccine in reduced schedules we employed a computational approach. The computer model developed allowed us to test in silico specific vaccination schedules in the quest for optimality. Specifically here we present a parallel genetic algorithm able to suggest optimal vaccination schedule.

Results & Conclusions: The enormous complexity of combinatorial space to be explored makes this approach the only possible one. The suggested schedule was then tested in vivo, giving good results. Finally, biologically relevant outcomes of optimization are presented.

Citing Articles

Translatability and transferability of in silico models: Context of use switching to predict the effects of environmental chemicals on the immune system.

Pappalardo F, Russo G, Corsini E, Paini A, Worth A Comput Struct Biotechnol J. 2022; 20:1764-1777.

PMID: 35495116 PMC: 9035946. DOI: 10.1016/j.csbj.2022.03.024.

References

Pappalardo F, Pennisi M, Castiglione F, Motta S . Vaccine protocols optimization: in silico experiences. Biotechnol Adv. 2009; 28(1):82-93. DOI: 10.1016/j.biotechadv.2009.10.001. View

Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V . In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res. 2010; 70(20):7755-63. DOI: 10.1158/0008-5472.CAN-10-0701. View

Pappalardo F, Martinez Forero I, Pennisi M, Palazon A, Melero I, Motta S . SimB16: modeling induced immune system response against B16-melanoma. PLoS One. 2011; 6(10):e26523. PMC: 3197530. DOI: 10.1371/journal.pone.0026523. View

Novellino L, Castelli C, Parmiani G . A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother. 2004; 54(3):187-207. PMC: 11032843. DOI: 10.1007/s00262-004-0560-6. View

Finn O . Cancer immunology. N Engl J Med. 2008; 358(25):2704-15. DOI: 10.1056/NEJMra072739. View

Dunn G, Old L, Schreiber R . The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2):137-48. DOI: 10.1016/j.immuni.2004.07.017. View

Agur Z . Biomathematics in the development of personalized medicine in oncology. Future Oncol. 2006; 2(1):39-42. DOI: 10.2217/14796694.2.1.39. View

Pennisi M, Pappalardo F, Palladini A, Nicoletti G, Nanni P, Lollini P . Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics. 2010; 11 Suppl 7:S13. PMC: 2957681. DOI: 10.1186/1471-2105-11-S7-S13. View

Ursini-Siegel J, Schade B, Cardiff R, Muller W . Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer. 2007; 7(5):389-97. DOI: 10.1038/nrc2127. View

10.

Pennisi M, Catanuto R, Pappalardo F, Motta S . Optimal vaccination schedules using simulated annealing. Bioinformatics. 2008; 24(15):1740-2. DOI: 10.1093/bioinformatics/btn260. View

11.

Lollini P, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C . Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets. 2010; 12(13):1957-73. DOI: 10.2174/138945011798184146. View

12.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A . Antimetastatic activity of a preventive cancer vaccine. Cancer Res. 2007; 67(22):11037-44. DOI: 10.1158/0008-5472.CAN-07-2499. View

13.

Alemani D, Pappalardo F, Pennisi M, Motta S, Brusic V . Combining cellular automata and Lattice Boltzmann method to model multiscale avascular tumor growth coupled with nutrient diffusion and immune competition. J Immunol Methods. 2011; 376(1-2):55-68. DOI: 10.1016/j.jim.2011.11.009. View

14.

Halling-Brown M, Pappalardo F, Rapin N, Zhang P, Alemani D, Emerson A . ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale. Philos Trans A Math Phys Eng Sci. 2010; 368(1920):2799-815. DOI: 10.1098/rsta.2010.0067. View

15.

Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini P . 2011: the immune hallmarks of cancer. Cancer Immunol Immunother. 2011; 60(3):319-26. PMC: 3042096. DOI: 10.1007/s00262-010-0968-0. View

16.

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

17.

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F . Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 2001; 194(9):1195-205. PMC: 2195980. DOI: 10.1084/jem.194.9.1195. View

18.

Pappalardo F, Halling-Brown M, Rapin N, Zhang P, Alemani D, Emerson A . ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Brief Bioinform. 2009; 10(3):330-40. DOI: 10.1093/bib/bbp014. View

19.

Lollini P, Cavallo F, Nanni P, Forni G . Vaccines for tumour prevention. Nat Rev Cancer. 2006; 6(3):204-16. DOI: 10.1038/nrc1815. View

20.

De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A . Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res. 2004; 64(11):4001-9. DOI: 10.1158/0008-5472.CAN-03-2984. View